Programmed Death-Ligand 1

Recent Findings on Programmed Death-Ligand 1

• A study of glioblastoma and colorectal cancer investigated conserved miRNA regulators of the PD-1/PD-L1/PD-L2 axis. The authors identified miRNAs dysregulated in both diseases that correlated with survival and showed inverse relationships with expression of PD-1, PD-L1, and PD-L2, linking post-transcriptional regulation to tumor immune microenvironment biology 42616478Aug.

• Research in gastric cancer examined PRKX-mediated stabilization of PD-L1 and characterized an immunosuppressive tumor subtype. A high density of PanCK-positive, PRKX-positive, PD-L1-positive tumor cells was associated with poor prognosis and served as a biomarker predicting 5-year survival among patients treated with anti-PD-1 therapy 42716706Sep. This work extends PD-L1 research into tumor-cell-state definition and prediction of immunotherapy outcomes.

• Medicinal-chemistry work addressed the limited aqueous solubility reported for many small-molecule PD-1/PD-L1 inhibitors. The study described the discovery and crystallographic investigation of water-soluble quaternary ammonium-based inhibitors and evaluated their anti-angiogenic activity, positioning direct checkpoint disruption alongside angiogenesis control 42720488Sep.

• The HighMorph computational framework was used for de novo cyclic peptide sequence design through protein–protein interaction recapitulation. PD-L1 was one of two clinically relevant targets used for systematic validation, alongside kallikrein-related peptidase 4, indicating an effort to expand the molecular formats available for disrupting immunosuppressive protein interactions 42720486Sep.

• A review of immunity and angiogenesis in lung adenocarcinoma discussed preclinical evidence that lenvatinib enhanced the efficacy of combined radiotherapy and PD-L1 blockade. The proposed therapeutic logic integrates vascular remodeling with antitumor immunity and is particularly relevant to tumors in which angiogenesis contributes to an unfavorable tumor microenvironment 42708433Sep.

• In cervical squamous cell carcinoma, GMPS was studied as a regulator of immune evasion through USP7-mediated deubiquitination of PD-L1. GMPS knockdown reduced tumor-cell proliferation, increased the toxicity and activity of CD8-positive T cells, reduced CD8-positive T-cell apoptosis, and lowered PD-L1 protein levels, implicating protein deubiquitination in control of the checkpoint ligand 42704520Sep.

• A study in non-small cell lung cancer investigated a PD-L1-induced PDK4/GLS metabolic axis as a mechanism contributing to resistance to anti-PD-1 therapy. The authors emphasized that, in addition to its established role as a ligand inhibiting T-cell function, PD-L1 may exert an intrinsic “reverse signaling” function that influences tumor metabolism and the immune landscape. The work therefore connects PD-L1 targeting with metabolic intervention 42686373Sep.

• In murine models of poorly immunogenic metastatic tumors, investigators combined dual immune checkpoint blockade with in situ vaccination and low-dose targeted radionuclide therapy. The checkpoint component included anti-PD-L1 and anti-CTLA-4, while the vaccination strategy used focal radiotherapy, intratumoral tumor-specific monoclonal antibody, and interleukin-2 to prime antitumor immunity; low-dose radionuclide therapy was used to propagate the response 42418729Jul. This approach places PD-L1 blockade within a multimodal strategy for metastasis and weakly immunogenic tumors.

• Atezolizumab was used to develop the PD-L1-targeted immuno-imaging agent ^89Zr-DFO-atezolizumab for colorectal cancer. The study evaluated the agent’s in vitro and in vivo specificity and its pharmacokinetic behavior, supporting the use of immuno-PET to assess PD-L1 as a noninvasive imaging target 42119829May.

• A nanoplatform for triple-negative breast cancer integrated a natural cyclooxygenase-2 inhibitor with paclitaxel and manganese-containing components to combine chemotherapy with immune activation. The study reported that paclitaxel-triggered pyroptosis upregulated the COX-2/PGE2/PD-L1 axis, which constrained immune amplification and made pyroptosis an intrinsically unstable immunogenic event. The findings support simultaneous targeting of inflammatory signaling and PD-L1 during cancer treatment 42102776May.

• A large clinical cohort of patients with oral squamous cell carcinoma was analyzed to investigate the prognostic significance of PD-L1 expression, primarily in patients treated surgically. This work evaluates PD-L1 as a clinical marker in squamous cell carcinoma, complementing mechanistic studies of PD-L1 regulation in cervical squamous cell carcinoma 42665707Aug.

• Collectively, these publications extend the principal research themes of PD-L1 targeting in cancer, multimodal cancer immunotherapy, and PD-L1-associated biology in squamous cell carcinoma. Across the studies, PD-L1 is examined as an immune checkpoint, a metabolically active signaling component, a regulated protein whose stability can be altered by ubiquitination pathways, a prognostic or predictive biomarker, and a target for antibodies, small molecules, cyclic peptides, and molecular imaging agents.